Rheumatoid Arthritis News

More trials are needed to fully elucidate the cardiovascular, infection and malignancy risks linked to Janus kinase inhibitors in rheumatoid arthritis, said a presenter at the 2022 Association of Women in Rheumatology annual conference.

The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting psoriatic arthritis, lupus and other indications, noted a presenter at the 2022 Association of Women in Rheumatology conference.

The next new treatment for rheumatoid arthritis could come from the unlikeliest of sources. Researchers based at Seattle Children’s Hospital spent the last several years studying the potential use of mini-proteins found in scorpion venom toxin — not to poison, but to help heal.

LOUISVILLE, Ky. — Persistent, chronic inflammation seen in moderate to severe psoriasis is associated with plaque destabilization and rupture that drives MI, and biologic treatment can reduce CV risk, according to a speaker.

ORLANDO — Medical cannabis is growing in acceptance and has benefits for managing pain in patients with rheumatic diseases, but more research is required, a presenter said at the 2022 Rheumatology Nurses Society Conference.

ORLANDO — Altered gut flora has the potential to impact autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, noted a speaker at the 2022 Rheumatology Nurses Society Conference.

ORLANDO — Lifestyle modifications such as exercise and an anti-inflammatory diet can improve the well-being of patients being treated for autoimmune diseases, said a presenter at the 2022 Rheumatology Nurses Society Conference.

ORLANDO — Understanding the nature and role of the synovium and synovial fluid is critical to managing various types of arthritis, according to a presenter at the 2022 Rheumatology Nurses Society Annual Conference.

The incidence of acute exacerbation was nearly one-third in patients with rheumatoid arthritis-associated interstitial lung disease, researchers reported in Chest.

Therapy discontinuance and 1-year response rates for Janus kinase and interleukin-6 inhibitors are similar to those of TNF inhibitors in patients with rheumatoid arthritis, according to data published in Annals of the Rheumatic Diseases.